The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Open accessAbstract
BACKGROUND The melanocortin 4 receptor (MC4R), a component of the leptin-melanocortin pathway, plays a part in bodyweight regulation. Severe early-onset obesity can be caused by biallelic variants in genes that affect the MC4R pathway. We report the results from trials of the MC4R agonist setmelanotide in individuals with severe obesity due to either pro-opiomelanocortin (POMC) deficiency obesity or leptin receptor (LEPR) deficiency obesity. METHODS These single-arm, open-label, multicentre, phase 3 trials were done in ten hospitals across Canada, the USA, Belgium, France, Germany, the Netherlands, and the UK. Participants aged 6 years or older with POMC or LEPR deficiency obesity received open-label setmelanotide for 12 weeks. Participants with at least 5 kg weight loss (or ≥5% if weighing <100 kg at baseline) entered an 8-week placebo-controlled withdrawal sequence (including 4 weeks each of blinded setmelanotide and placebo treatment) followed by 32 additional weeks of open-label treatment. The primary endpoint, which was assessed in participants who received at least one dose of study medication and had a baseline assessment (full analysis set), was the proportion of participants with at least 10% weight loss compared with baseline at approximately 1 year. A key secondary endpoint was mean percentage change in the most hunger score of the 11-point Likert-type scale at approximately 1 year on the therapeutic dose, which was assessed in a subset of participants aged 12 year…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Injection site reactions, hyperpigmentation, and nausea are common. Skin darkening occurred in ~60% of trial participants. No serious long-term safety concerns have been observed [78].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [78]
In the citing paper
“In trials, 80% of patients with POMC deficiency and 45% with LEPR deficiency achieved ≥10% weight loss over one year. Hunger scores also improved dramatically.”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [78]
In the citing paper
“Setmelanotide (Imcivree®) was approved in 2020 for obesity due to proopiomelanocortin (POMC), leptin receptor (LEPR), or PCSK1 deficiency, and later for Bardet–Biedl syndrome [78].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [78]
In the citing paper
“may be used in this age range (genotype-restricted) [108].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [108]
In the citing paper
“Approved from age 2, but limited to specific genetic disorders (e.g., biallelic POMC, LEPR, Bardet-Biedl syndrome) [108], and may be used in this age range (genotype-restricted).”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [108]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Targeted disruption of the melanocortin-4 receptor results in obesity in mice
Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Berkemeier, L. R., Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)81865-6 · Cited by 3,030
A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
Clément, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., Gourmelen, M., Dina, C., Chambaz, J., Lacorte, J.-M., et al. (1998) · Nature · doi:10.1038/32911 · Cited by 2,346
Self-citationChanges in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Krude, H., Biebermann, H., Luck, W., Horn, R., Brabant, G., & Grüters, A. (1998) · Nature Genetics · doi:10.1038/509 · Cited by 1,733
Jackson, R. S., Creemers, J. W. M., Ohagi, S., Raffin-Sanson, M.-L., Sanders, L., Montague, C. T., Hutton, J. C., & O'Rahilly, S. (1997) · Nature Genetics · doi:10.1038/ng0797-303 · Cited by 1,153
Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.
Farooqi, I. S., Wangensteen, T., Collins, S., Kimber, W., Matarese, G., Keogh, J. M., Lank, E., Bottomley, B., Lopez-Fernandez, J., Ferraz-Amaro, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063988 · Cited by 732
Self-citationToward a Wiring Diagram Understanding of Appetite Control
Andermann, M. L., & Lowell, B. B. (2017) · Neuron · doi:10.1016/j.neuron.2017.06.014 · Cited by 606
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
Kühnen, P., Clément, K., Wiegand, S., Blankenstein, O., Gottesdiener, K., Martini, L. L., Mai, K., Blume-Peytavi, U., Grüters, A., & Krude, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512693 · Cited by 485
Self-citationModulation of Blood Pressure by Central Melanocortinergic Pathways
Greenfield, J. R., Miller, J. W., Keogh, J. M., Henning, E., Satterwhite, J. H., Cameron, G. S., Astruc, B., Mayer, J. P., Brage, S., See, T. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803085 · Cited by 477
Self-citation
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
The genetics of obesity: From discovery to biology
Loos, R. J. F., & Yeo, G. S. H. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00414-z · Cited by 1,291
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Obesity in children and adolescents: epidemiology, causes, assessment, and management
Jebeile, H., Kelly, A. S., O'Malley, G., & Baur, L. A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00047-x · Cited by 1,099
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738
Self-citation
Metadata
- Authors
- Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W. K., Connors, H., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G., Kohlsdorf, K., Poitou, C., Puder, L., Swain, J., Stewart, M., Yuan, G., Wabitsch, M., Kühnen, P., Pigeon-Kherchiche, P., Flaus-Furmaniuk, A., Bald, M., Denzer, C., von Schnurbein, J., Abawi, O., Blume-Peytavi, U., Krabusch, P., Mai, K., Schnabel, D., Wiegand, S., Flück, C. E., Schulz, E., Voss, E., Bratina, N., Weiss, K., Martos-Moreno, G. Á., Danset, A., Gougis, P., Dubern, B., Clément, K., van den Akker, E. L. T., Argente, J., Bahm, A. L., Chung, W. K., Connors, H. S., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G. A., Poitou, C., Puder, L., Swain, J. M., Stewart, M. W., Yuan, G., Wabitsch, M., & Kühnen, P.
- Affiliations
- Inserm (FR)
- Universität Ulm (DE)
- Nutrition et obésité : approches systémiques (FR)
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 8
- Issue
- 12
- Pages
- 960-970
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3095455148
- Cited by
- 492
- References
- 30
- Citations by year
- 2026: 75 · 2025: 88 · 2024: 100 · 2023: 97 · 2022: 76 · 2021: 55 · 2020: 1
- FWCI
- 29.79
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- National Institute for Health and Care Research (NF-SI-0616-10065)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- setmelanotide, melanocortin-4 receptor agonist, morbid obesity, weight loss, hunger, leptin-melanocortin pathway, adverse events, childhood obesity, early-onset obesity, drug safety and efficacy, obesity pharmacotherapy
- MeSH terms
- Adolescent, Adrenal Insufficiency, Adult, alpha-MSH, Child, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Obesity, Pro-Opiomelanocortin, Prognosis, Anti-Obesity Agents, Receptor, Melanocortin, Type 4, Receptors, Leptin, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. https://app.cochat.ai/papers/10.1016/s2213-8587(20)30364-8
- The paper
- Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W. K., Connors, H., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G., Kohlsdorf, K., Poitou, C., Puder, L., Swain, J., Stewart, M., Yuan, G., Wabitsch, M., Kühnen, P., Pigeon-Kherchiche, P., . . . Kühnen, P. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(20)30364-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.